Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Pyrimidinyl Biphenylureas Act as Allosteric Modulators to activate Cannabinoid Receptor 1 and initiate β-Arrestin-dependent Responses

Caitlin A.D. Jagla, Caitlin E. Scott, Yaliang Tang, Changjiang Qiao, Gabriel E. Mateo-Semidey, Guillermo A. Yudowski, Dai Lu and Debra A. Kendall
Molecular Pharmacology October 15, 2018, mol.118.112854; DOI: https://doi.org/10.1124/mol.118.112854
Caitlin A.D. Jagla
1 University of Connecticut;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caitlin E. Scott
1 University of Connecticut;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yaliang Tang
1 University of Connecticut;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Changjiang Qiao
2 Texas A&M University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabriel E. Mateo-Semidey
3 University of Puerto Rico;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guillermo A. Yudowski
3 University of Puerto Rico;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dai Lu
4 Texas A and M
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Debra A. Kendall
1 University of Connecticut;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

CB1 is a G protein coupled receptor (GPCR) abundant in the central nervous system. It binds several compounds in its orthosteric site, including the endocannabinoids, arachidonoyl ethanolamide (anandamide; AEA) and 2-arachidonoyl glycerol (2-AG), and the plant-derived Δ9-tetrahydrocannabinol (THC), one of the main psychoactive components of marijuana. It primarily couples to Gi/o proteins to inhibit adenylate cyclase activity and typically induces downstream signaling that is Gi-dependent. Since this receptor is implicated in several maladies, such as obesity, pain, and neurodegenerative disorders, there is interest in developing therapeutics that selectively target this receptor. Allosteric modulators of CB1 offer one new approach that has tremendous therapeutic potential. Here, we reveal receptor- and cellular-level properties consistent with receptor activation by a series of pyrimidinyl biphenylureases (LDK1285, LDK1288, LDK1305, and PSNCBAM1). This includes promoting binding of the agonist CP55940 with positive cooperativity and inhibiting binding of the inverse agonist SR141716A with negative cooperativity. Consistent with these findings, the allosteric modulators induced cellular internalization of the receptor and recruitment of β-arrestin 2 in HEK293 cells monitored with confocal and TIRF microscopy, respectively. These allosteric modulators, however, cause G protein-independent but β-arrestin 1-dependent phosphorylation of the downstream kinases, ERK1/2, MEK, and Src using immunoblotting studies. These results are consistent with the involvement of β-arrestin and suggest these allosteric modulators induce biased signaling.

  • Allosterism
  • Cannabinoid receptors
  • The American Society for Pharmacology and Experimental Therapeutics
Next
Back to top

In this issue

Molecular Pharmacology: 99 (3)
Molecular Pharmacology
Vol. 99, Issue 3
1 Mar 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pyrimidinyl Biphenylureas Act as Allosteric Modulators to activate Cannabinoid Receptor 1 and initiate β-Arrestin-dependent Responses
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Pyrimidinyl Biphenylureas Act as Allosteric Modulators to activate Cannabinoid Receptor 1 and initiate β-Arrestin-dependent Responses

Caitlin A.D. Jagla, Caitlin E. Scott, Yaliang Tang, Changjiang Qiao, Gabriel E. Mateo-Semidey, Guillermo A. Yudowski, Dai Lu and Debra A. Kendall
Molecular Pharmacology October 15, 2018, mol.118.112854; DOI: https://doi.org/10.1124/mol.118.112854

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Pyrimidinyl Biphenylureas Act as Allosteric Modulators to activate Cannabinoid Receptor 1 and initiate β-Arrestin-dependent Responses

Caitlin A.D. Jagla, Caitlin E. Scott, Yaliang Tang, Changjiang Qiao, Gabriel E. Mateo-Semidey, Guillermo A. Yudowski, Dai Lu and Debra A. Kendall
Molecular Pharmacology October 15, 2018, mol.118.112854; DOI: https://doi.org/10.1124/mol.118.112854
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Identification of Celecoxib targets by label-free TPP
  • Editing TOP2α Intron 19 5′ SS Circumvents Drug Resistance
  • CTS Bias
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics